Qureight and Avalyn Launch Strategic Partnership in Progressive Pulmonary Fibrosis
Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat life-threatening pulmonary diseases, today announce the initiation of a strategic partnership in progressive pulmonary fibrosis, commencing with the ongoing MIST study, a Phase 2b clinical trial evaluating the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF).